Product information
From Health Canada
Note - The product information found within this database originates from organizations not subject to the Official Languages Act and is available in the language in which it was written and submitted to Health Canada.
Note - The market status of a product is now available in the LNHPD and identifies if a product is "marketed" or "not marketed" in Canada. Product licence holders may voluntarily provide the Natural and Non-Prescription Health Products Directorate (NNHPD) with information about whether their product is currently available to Canadian consumers. Where no information has been provided, the default status is "not marketed". The "current status" field remains unaffected and will continue to indicate the status of the product licence (i.e., active, discontinued, stop sale, cancelled, or suspended). Note that where a licence has been suspended, cancelled or under stop sale, the product cannot be legally sold in Canada.
Product licence holders - if you wish to update a product's market status, you are invited to complete the Natural Health Products Market Notification Web Form. As with all other notifications, there is no current service standard. The NNHPD will process the market status update as soon as feasible, based on its available resources. As a reminder, market notification is voluntary; therefore, a licence holder is not required to wait for the LNHPD to be updated before a licensed product is sold in Canada. As such, products that are identified in the LNHPD as "not marketed" may still be sold in Canada.
- Natural Product Number (NPN):
- 80047562
- Market status:
- Marketed
- Licence Status:
- Active
- Brand name(s):
- Jamp-Sodium Phosphate
- Licence holder:
- JAMP Pharma Corporation
- Dosage Form:
- Tablet, effervescent
- Recommended route of administration:
-
Oral
Sub population (Sub Pop.) | Quantity (Qty) | Frequency (Freq.) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sub Pop. | Age | Min. | Max. | UoM Footnote1 Age | Qty | Min. | Max. | UoM Qty | Freq. | Min. | Max. | UoM Freq. |
Adults | 1.0 | tablet | 1 | 2 | daily | |||||||
- Recommended use or purpose:
- Hypercalciuria, electrolyte replenisher.
- Risk Information:
- Cautions and Warnings
- Consult a health care practitioner prior to use if you have a cardiac disease treated with digitalis, adrenal insufficiency, acute dehydration, severe renal insufficiency, cardiac failure, liver cirrhosis or severe hepatic disease, edema, hypernatremia, hypertension or toxaemia of pregnancy. Do not use if hyperphosphatemia is present or in the presence of severe impairment of renal function (less than 30% of normal).
- Known Adverse Reactions
- The following reactions have been reported: Nausea, vomiting, stomach pain, laxative effect or diarrhea, and less frequently: Fluid retention associated with swelling of feet and/or weight gain, hyperkalemia associated with confusion, tiredness or weakness; irregular or slow heart beat; numbness or tingling around lips, hands or feet; unexplained anxiety; breathing problems, hypernatremia associated with confusion; tiredness or weakness; convulsions; decrease in urine volume or in frequency of urine; fast heartbeat; headache or dizziness; increased thirst; hyperphosphatemia or hypocalcemic tetany associated with muscle cramps; numbness, tingling, pain, or weakness in hands or feet, shortness of breath or troubled breathing.
Medicinal ingredients | Quantity (Qty) | Extract | Potency |
---|---|---|---|
Phosphorus |
500.0 mg
|
||
Potassium |
123.0 mg
|
||
Sodium |
469.0 mg
|
- List of non-medicinal ingredients:
-
- Citric Acid Anhydrous
- Flavour
- Polyethylene Glycol
- Saccharin sodium
- Sucrose
- simethicone
- Date of licensing:
- 2014-01-14
- Revised date of licence:
- 2023-09-14
Application information
Related information
Contact us
For technical support or if you have general questions concerning the content of this database, please contact the Natural Health Products Directorate (NHPD).